First in vivo car-m lead candidate nominated under carisma-moderna collaboration

First lead candidate to address a solid tumor indication with significant unmet medical need supportive pre-clinical proof of concept data reported at sitc 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo car-m therapy utilizing mrna/lnps in solid tumors philadelphia , dec. 14, 2023 /prnewswire/ -- carisma therapeutics inc. (nasdaq: carm) ("carisma" or the "company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with moderna, inc. (nasdaq: mrna). this first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.
MRNA Ratings Summary
MRNA Quant Ranking